Shopping Cart 0
Cart Subtotal
USD 0

Immunohematology - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 8000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 12000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Immunohematology-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Immunohematology-Medical Devices Pipeline Assessment, 2018" provides an overview of Immunohematology currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohematology pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Immunohematology under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Immunohematology and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Immunohematology under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Immunohematology Overview 6

3 Products under Development 7

3.1 Immunohematology-Pipeline Products by Stage of Development 7

3.2 Immunohematology-Pipeline Products by Segment 8

3.3 Immunohematology-Pipeline Products by Territory 9

3.4 Immunohematology-Pipeline Products by Regulatory Path 10

3.5 Immunohematology-Pipeline Products by Estimated Approval Date 11

4 Immunohematology-Pipeline Products under Development by Companies 12

4.1 Immunohematology Companies-Pipeline Products by Stage of Development 12

4.2 Immunohematology-Pipeline Products by Stage of Development 13

5 Immunohematology Companies and Product Overview 15

5.1 AbSorber AB Company Overview 15

5.2 Amity University Company Overview 16

5.3 Arizona State University Company Overview 17

5.4 Biofortuna Ltd Company Overview 18

5.5 Grifols SA Company Overview 23

5.6 Haemonetics Corp Company Overview 24

5.7 Immucor, Inc. Company Overview 25

5.8 Ortho-Clinical Diagnostics Inc Company Overview 26

5.9 Quotient Limited Company Overview 28

5.10 TBG Diagnostics Ltd Company Overview 34

5.11 Transfusion & Transplantation Technologies (Inactive) Company Overview 37

6 Immunohematology- Recent Developments 42

6.1 Jun 18, 2018: Quotient Reports Concordance Data from the MosaiQ European Field Trial 42

6.2 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 43

6.3 Jun 01, 2018: ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics 43

6.4 May 29, 2018: Quotient Names Franz Walt As Chief Executive Officer 44

6.5 May 29, 2018: Quotient Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ European Field Trials 45

6.6 May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 47

6.7 May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 48

6.8 May 17, 2018: Quotient Reports Commencement of EU Blood Grouping Field Trial 49

6.9 May 15, 2018: Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear 49

6.10 May 14, 2018: Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents 51

6.11 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer 52

6.12 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results 52

6.13 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance 53

6.14 May 08, 2018: Ortho Clinical Diagnostics Holds Summit to Help Asia-Pacific Lab Leaders Envision the Lab of the Future 55

6.15 May 03, 2018: Siemens Healthineers fully on track to meet the targets 55

6.16 May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 56

6.17 Apr 10, 2018: Theradiag reports its 2017 annual results and sales for first quarter 2018 60

6.18 Mar 28, 2018: Medix Biochemica Launch NT-proBNP antibody 1309 available 62

6.19 Mar 26, 2018: Quotient Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction 62

6.20 Mar 26, 2018: Quotient Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer 63

6.21 Feb 27, 2018: Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results 64

6.22 Feb 20, 2018: Quotient Announces Appointment of Franz Walt as Non-Executive Director 66

6.23 Feb 20, 2018: Quotient Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility 66

6.24 Feb 20, 2018: Theradiag Announces 2017 Annual Sales and Cash Flow at End 2017 67

6.25 Feb 06, 2018: Haemonetics 3rd Quarter Fiscal 2018 Earnings 67

6.26 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics 69

6.27 Jan 25, 2018: Ellen M. Zane Rejoins Haemonetics Board of Directors 70

6.28 Jan 16, 2018: Avi Pelossof Appointed President and CEO of Immucor 70

6.29 Dec 19, 2017: THERADIAG provides an update on Prestizia and its partnership with HOB Biotech 71

6.30 Nov 29, 2017: Siemens plans to list Siemens Healthineers on Frankfurt Stock Exchange 72

6.31 Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 72

6.32 Nov 02, 2017: Bio-Rad Reports Third-Quarter 2017 Financial Results 76

6.33 Oct 30, 2017: Quotient Reports Second Quarter Fiscal 2018 Financial Results 77

6.34 Oct 26, 2017: Theradiag: Revenues at the end of September 30, 2017 79

6.35 Oct 24, 2017: SYGNIS announces the launch of the Universal Lateral Flow Assay kit and associated patent filing 79

6.36 Oct 18, 2017: Robert E. Abernathy Joins Haemonetics Board of Directors 80

6.37 Oct 02, 2017: Ortho Clinical Diagnostics to Present Data on Automation in Immunohematology and Demonstrate Its Entire Transfusion Medicine Portfolio at the 2017 AABB Annual Meeting 80

6.38 Sep 19, 2017: Theradiag: Results and activity for the first half of 2017 Continued improvement in results 81

6.39 Sep 12, 2017: Quotient Reports Results From Latest MosaiQ Performance Evaluation Studies involving MosaiQ IH Microarray 83

6.40 Aug 07, 2017: Quotient Reports Results From Ongoing MosaiQ Performance Evaluation Studies and First Quarter Fiscal 2018 Financial Results 84

6.41 Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results 86

6.42 Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 87

6.43 Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 94

7 Appendix 95

7.1 Methodology 95

7.2 About GlobalData 98

7.3 Contact Us 98

7.4 Disclaimer 98


List Of Figure

1.2 List of Figures

Figure 1: Immunohematology-Pipeline Products by Stage of Development 7

Figure 2: Immunohematology-Pipeline Products by Segment 8

Figure 3: Immunohematology-Pipeline Products by Territory 9

Figure 4: Immunohematology-Pipeline Products by Regulatory Path 10

Figure 5: Immunohematology-Pipeline Products by Estimated Approval Date 11


List Of Table

1.1 List of Tables

Table 1: Immunohematology-Pipeline Products by Stage of Development 7

Table 2: Immunohematology-Pipeline Products by Segment 8

Table 3: Immunohematology-Pipeline Products by Territory 9

Table 4: Immunohematology-Pipeline Products by Regulatory Path 10

Table 5: Immunohematology-Pipeline Products by Estimated Approval Date 11

Table 6: Immunohematology Companies-Pipeline Products by Stage of Development 12

Table 7: Immunohematology-Pipeline Products by Stage of Development 13

Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: ABO Diagnostic Test-Product Status 15

Table 10: ABO Diagnostic Test-Product Description 15

Table 11: Amity University Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Blood Group Testing Kit-Product Status 16

Table 13: Blood Group Testing Kit-Product Description 16

Table 14: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: Blood Screening Immunosignaturing-Product Status 17

Table 16: Blood Screening Immunosignaturing-Product Description 17

Table 17: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 18

Table 18: HemoPlex Kell Genotyping Kit-Product Status 18

Table 19: HemoPlex Kell Genotyping Kit-Product Description 18

Table 20: HemoPlex Kidd & Duffy Genotyping Kit-Product Status 19

Table 21: HemoPlex Kidd & Duffy Genotyping Kit-Product Description 19

Table 22: HemoPlex MNS Genotyping Kit-Product Status 19

Table 23: HemoPlex MNS Genotyping Kit-Product Description 19

Table 24: HemoPlex Multi Blood Group Genotyping Kit-Product Status 20

Table 25: HemoPlex Multi Blood Group Genotyping Kit-Product Description 20

Table 26: HemoPlex RHCE Screening Kit-Product Status 20

Table 27: HemoPlex RHCE Screening Kit-Product Description 20

Table 28: HemoPlex RHCE Variant Genotyping Kit-Product Status 21

Table 29: HemoPlex RHCE Variant Genotyping Kit-Product Description 21

Table 30: HemoPlex RHD & CE Genotyping Kit-Product Status 21

Table 31: HemoPlex RHD & CE Genotyping Kit-Product Description 21

Table 32: HemoPlex RHD Variant Genotyping Kit-Product Status 22

Table 33: HemoPlex RHD Variant Genotyping Kit-Product Description 22

Table 34: ThromboPlex HPA Screening Kit-Product Status 22

Table 35: ThromboPlex HPA Screening Kit-Product Description 22

Table 36: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 23

Table 37: IH Blood Genotyping (D) Kit-Product Status 23

Table 38: IH Blood Genotyping (D) Kit-Product Description 23

Table 39: Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 24

Table 40: Blood Typing System-Product Status 24

Table 41: Blood Typing System-Product Description 24

Table 42: Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25

Table 43: NEO Iris-Product Status 25

Table 44: NEO Iris-Product Description 25

Table 45: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 46: ORTHO AutoVue-Rare Sera Assay-Product Status 26

Table 47: ORTHO AutoVue-Rare Sera Assay-Product Description 26

Table 48: ORTHO BioVue-Rare Sera Assay-Product Status 27

Table 49: ORTHO BioVue-Rare Sera Assay-Product Description 27

Table 50: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 28

Table 51: ALBAclone Anti-C beta Reagent-Product Status 28

Table 52: ALBAclone Anti-C beta Reagent-Product Description 29

Table 53: ALBAclone Anti-e beta Reagent-Product Status 29

Table 54: ALBAclone Anti-e beta Reagent-Product Description 29

Table 55: ALBAclone Anti-H Reagent-Product Status 29

Table 56: ALBAclone Anti-H Reagent-Product Description 30

Table 57: ALBAcyte O Adult i Cell Reagent-Product Status 30

Table 58: ALBAcyte O Adult i Cell Reagent-Product Description 30

Table 59: ALBAcyte O RhD VI Reagent Cells-Product Status 30

Table 60: ALBAcyte O RhD VI Reagent Cells-Product Description 31

Table 61: Eluate Kit-Product Status 31

Table 62: Eluate Kit-Product Description 31

Table 63: MosaiQ IH Microarray-Product Status 31

Table 64: MosaiQ IH Microarray-Product Description 32

Table 65: Polyagglutionation Kit-Product Status 32

Table 66: Polyagglutionation Kit-Product Description 32

Table 67: Sensitivity Kit Anti-S, K, e, C-Product Status 32

Table 68: Sensitivity Kit Anti-S, K, e, C-Product Description 33

Table 69: TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

Table 70: HLAssure SE A Locus SBT Kit-Product Status 34

Table 71: HLAssure SE A Locus SBT Kit-Product Description 34

Table 72: HLAssure SE B Locus SBT Kit-Product Status 35

Table 73: HLAssure SE B Locus SBT Kit-Product Description 35

Table 74: HLAssure SE C Locus SBT Kit-Product Status 35

Table 75: HLAssure SE C Locus SBT Kit-Product Description 35

Table 76: HLAssure SE DQB Locus SBT Kit-Product Status 36

Table 77: HLAssure SE DQB Locus SBT Kit-Product Description 36

Table 78: HLAssure SE DRB-EX Locus SBT Kit-Product Status 36

Table 79: HLAssure SE DRB-EX Locus SBT Kit-Product Description 36

Table 80: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 37

Table 81: Aegis-Anti-A Quantitation In Group O Platelets-Product Status 37

Table 82: Aegis-Anti-A Quantitation In Group O Platelets-Product Description 37

Table 83: Aegis-Antibody Screening And Identification Assay-Product Status 38

Table 84: Aegis-Antibody Screening And Identification Assay-Product Description 38

Table 85: Aegis-Blood Grouping Assay-Product Status 38

Table 86: Aegis-Blood Grouping Assay-Product Description 39

Table 87: Aegis-Platelet Cross-match Assay-Product Status 39

Table 88: Aegis-Platelet Cross-match Assay-Product Description 39

Table 89: Aegis-Residual A Quantitation Assay-Product Status 40

Table 90: Aegis-Residual A Quantitation Assay-Product Description 40

Table 91: Aegis-rWBC Quantitation Assay-Product Status 40

Table 92: Aegis-rWBC Quantitation Assay-Product Description 40

Table 93: AEGIS System-Product Status 41

Table 94: AEGIS System-Product Description 41

Table 95: Glossary 97

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

AbSorber AB, ABO Diagnostic Test; Amity University, Blood Group Testing Kit; Arizona State University, Blood Screening Immunosignaturing; Biofortuna Ltd, HemoPlex Kell Genotyping Kit; Biofortuna Ltd, HemoPlex Kidd &; Duffy Genotyping Kit; Biofortuna Ltd, HemoPlex MNS Genotyping Kit; Biofortuna Ltd, HemoPlex Multi Blood Group Genotyping Kit; Biofortuna Ltd, HemoPlex RHCE Screening Kit; Biofortuna Ltd, HemoPlex RHCE Variant Genotyping Kit; Biofortuna Ltd, HemoPlex RHD &; CE Genotyping Kit; Biofortuna Ltd, HemoPlex RHD Variant Genotyping Kit; Biofortuna Ltd, ThromboPlex HPA Screening Kit; Grifols SA, IH Blood Genotyping (D) Kit; Haemonetics Corp, Blood Typing System; Immucor, Inc., NEO Iris; Ortho-Clinical Diagnostics Inc, ORTHO AutoVue - Rare Sera Assay; Ortho-Clinical Diagnostics Inc, ORTHO BioVue - Rare Sera Assay; Quotient Limited, ALBAclone Anti-C beta Reagent; Quotient Limited, ALBAclone Anti-e beta Reagent; Quotient Limited, ALBAclone Anti-H Reagent; Quotient Limited, ALBAcyte O Adult i Cell Reagent; Quotient Limited, ALBAcyte O RhD VI Reagent Cells; Quotient Limited, Eluate Kit; Quotient Limited, MosaiQ IH Microarray; Quotient Limited, Polyagglutionation Kit; Quotient Limited, Sensitivity Kit Anti-S, K, e, C; TBG Diagnostics Ltd, HLAssure SE A Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE B Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE C Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE DQB Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE DRB-EX Locus SBT Kit; Transfusion &; Transplantation Technologies (Inactive), Aegis - Anti-A Quantitation In Group O Platelets; Transfusion &; Transplantation Technologies (Inactive), Aegis - Antibody Screening And Identification Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Blood Grouping Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Platelet Cross-match Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Residual A Quantitation Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - rWBC Quantitation Assay; Transfusion &; Transplantation Technologies (Inactive), AEGIS System


Companies

AbSorber AB

Amity University

Arizona State University

Biofortuna Ltd

Grifols SA

Haemonetics Corp

Immucor, Inc.

Ortho-Clinical Diagnostics Inc

Quotient Limited

TBG Diagnostics Ltd

Transfusion & Transplantation Technologies

Immunohematology-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Immunohematology-Medical Devices Pipeline Assessment, 2018" provides an overview of Immunohematology currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunohematology pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Immunohematology under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Immunohematology and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Immunohematology under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Immunohematology Overview 6

3 Products under Development 7

3.1 Immunohematology-Pipeline Products by Stage of Development 7

3.2 Immunohematology-Pipeline Products by Segment 8

3.3 Immunohematology-Pipeline Products by Territory 9

3.4 Immunohematology-Pipeline Products by Regulatory Path 10

3.5 Immunohematology-Pipeline Products by Estimated Approval Date 11

4 Immunohematology-Pipeline Products under Development by Companies 12

4.1 Immunohematology Companies-Pipeline Products by Stage of Development 12

4.2 Immunohematology-Pipeline Products by Stage of Development 13

5 Immunohematology Companies and Product Overview 15

5.1 AbSorber AB Company Overview 15

5.2 Amity University Company Overview 16

5.3 Arizona State University Company Overview 17

5.4 Biofortuna Ltd Company Overview 18

5.5 Grifols SA Company Overview 23

5.6 Haemonetics Corp Company Overview 24

5.7 Immucor, Inc. Company Overview 25

5.8 Ortho-Clinical Diagnostics Inc Company Overview 26

5.9 Quotient Limited Company Overview 28

5.10 TBG Diagnostics Ltd Company Overview 34

5.11 Transfusion & Transplantation Technologies (Inactive) Company Overview 37

6 Immunohematology- Recent Developments 42

6.1 Jun 18, 2018: Quotient Reports Concordance Data from the MosaiQ European Field Trial 42

6.2 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 43

6.3 Jun 01, 2018: ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics 43

6.4 May 29, 2018: Quotient Names Franz Walt As Chief Executive Officer 44

6.5 May 29, 2018: Quotient Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ European Field Trials 45

6.6 May 25, 2018: Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends 47

6.7 May 23, 2018: Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency 48

6.8 May 17, 2018: Quotient Reports Commencement of EU Blood Grouping Field Trial 49

6.9 May 15, 2018: Prenatal testing of the foetal rhesus factor: test is reliable, but benefit is unclear 49

6.10 May 14, 2018: Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents 51

6.11 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer 52

6.12 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results 52

6.13 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance 53

6.14 May 08, 2018: Ortho Clinical Diagnostics Holds Summit to Help Asia-Pacific Lab Leaders Envision the Lab of the Future 55

6.15 May 03, 2018: Siemens Healthineers fully on track to meet the targets 55

6.16 May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales 56

6.17 Apr 10, 2018: Theradiag reports its 2017 annual results and sales for first quarter 2018 60

6.18 Mar 28, 2018: Medix Biochemica Launch NT-proBNP antibody 1309 available 62

6.19 Mar 26, 2018: Quotient Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction 62

6.20 Mar 26, 2018: Quotient Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer 63

6.21 Feb 27, 2018: Bio-Rad Reports Fourth-Quarter and Full-Year 2017 Financial Results 64

6.22 Feb 20, 2018: Quotient Announces Appointment of Franz Walt as Non-Executive Director 66

6.23 Feb 20, 2018: Quotient Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility 66

6.24 Feb 20, 2018: Theradiag Announces 2017 Annual Sales and Cash Flow at End 2017 67

6.25 Feb 06, 2018: Haemonetics 3rd Quarter Fiscal 2018 Earnings 67

6.26 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics 69

6.27 Jan 25, 2018: Ellen M. Zane Rejoins Haemonetics Board of Directors 70

6.28 Jan 16, 2018: Avi Pelossof Appointed President and CEO of Immucor 70

6.29 Dec 19, 2017: THERADIAG provides an update on Prestizia and its partnership with HOB Biotech 71

6.30 Nov 29, 2017: Siemens plans to list Siemens Healthineers on Frankfurt Stock Exchange 72

6.31 Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million 72

6.32 Nov 02, 2017: Bio-Rad Reports Third-Quarter 2017 Financial Results 76

6.33 Oct 30, 2017: Quotient Reports Second Quarter Fiscal 2018 Financial Results 77

6.34 Oct 26, 2017: Theradiag: Revenues at the end of September 30, 2017 79

6.35 Oct 24, 2017: SYGNIS announces the launch of the Universal Lateral Flow Assay kit and associated patent filing 79

6.36 Oct 18, 2017: Robert E. Abernathy Joins Haemonetics Board of Directors 80

6.37 Oct 02, 2017: Ortho Clinical Diagnostics to Present Data on Automation in Immunohematology and Demonstrate Its Entire Transfusion Medicine Portfolio at the 2017 AABB Annual Meeting 80

6.38 Sep 19, 2017: Theradiag: Results and activity for the first half of 2017 Continued improvement in results 81

6.39 Sep 12, 2017: Quotient Reports Results From Latest MosaiQ Performance Evaluation Studies involving MosaiQ IH Microarray 83

6.40 Aug 07, 2017: Quotient Reports Results From Ongoing MosaiQ Performance Evaluation Studies and First Quarter Fiscal 2018 Financial Results 84

6.41 Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results 86

6.42 Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions 87

6.43 Jul 25, 2017: Theradiag: Further Strong Sales Growth in the First Half of 2017: +9% 94

7 Appendix 95

7.1 Methodology 95

7.2 About GlobalData 98

7.3 Contact Us 98

7.4 Disclaimer 98


List Of Figure

1.2 List of Figures

Figure 1: Immunohematology-Pipeline Products by Stage of Development 7

Figure 2: Immunohematology-Pipeline Products by Segment 8

Figure 3: Immunohematology-Pipeline Products by Territory 9

Figure 4: Immunohematology-Pipeline Products by Regulatory Path 10

Figure 5: Immunohematology-Pipeline Products by Estimated Approval Date 11


List Of Table

1.1 List of Tables

Table 1: Immunohematology-Pipeline Products by Stage of Development 7

Table 2: Immunohematology-Pipeline Products by Segment 8

Table 3: Immunohematology-Pipeline Products by Territory 9

Table 4: Immunohematology-Pipeline Products by Regulatory Path 10

Table 5: Immunohematology-Pipeline Products by Estimated Approval Date 11

Table 6: Immunohematology Companies-Pipeline Products by Stage of Development 12

Table 7: Immunohematology-Pipeline Products by Stage of Development 13

Table 8: AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: ABO Diagnostic Test-Product Status 15

Table 10: ABO Diagnostic Test-Product Description 15

Table 11: Amity University Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Blood Group Testing Kit-Product Status 16

Table 13: Blood Group Testing Kit-Product Description 16

Table 14: Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: Blood Screening Immunosignaturing-Product Status 17

Table 16: Blood Screening Immunosignaturing-Product Description 17

Table 17: Biofortuna Ltd Pipeline Products & Ongoing Clinical Trials Overview 18

Table 18: HemoPlex Kell Genotyping Kit-Product Status 18

Table 19: HemoPlex Kell Genotyping Kit-Product Description 18

Table 20: HemoPlex Kidd & Duffy Genotyping Kit-Product Status 19

Table 21: HemoPlex Kidd & Duffy Genotyping Kit-Product Description 19

Table 22: HemoPlex MNS Genotyping Kit-Product Status 19

Table 23: HemoPlex MNS Genotyping Kit-Product Description 19

Table 24: HemoPlex Multi Blood Group Genotyping Kit-Product Status 20

Table 25: HemoPlex Multi Blood Group Genotyping Kit-Product Description 20

Table 26: HemoPlex RHCE Screening Kit-Product Status 20

Table 27: HemoPlex RHCE Screening Kit-Product Description 20

Table 28: HemoPlex RHCE Variant Genotyping Kit-Product Status 21

Table 29: HemoPlex RHCE Variant Genotyping Kit-Product Description 21

Table 30: HemoPlex RHD & CE Genotyping Kit-Product Status 21

Table 31: HemoPlex RHD & CE Genotyping Kit-Product Description 21

Table 32: HemoPlex RHD Variant Genotyping Kit-Product Status 22

Table 33: HemoPlex RHD Variant Genotyping Kit-Product Description 22

Table 34: ThromboPlex HPA Screening Kit-Product Status 22

Table 35: ThromboPlex HPA Screening Kit-Product Description 22

Table 36: Grifols SA Pipeline Products & Ongoing Clinical Trials Overview 23

Table 37: IH Blood Genotyping (D) Kit-Product Status 23

Table 38: IH Blood Genotyping (D) Kit-Product Description 23

Table 39: Haemonetics Corp Pipeline Products & Ongoing Clinical Trials Overview 24

Table 40: Blood Typing System-Product Status 24

Table 41: Blood Typing System-Product Description 24

Table 42: Immucor, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25

Table 43: NEO Iris-Product Status 25

Table 44: NEO Iris-Product Description 25

Table 45: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26

Table 46: ORTHO AutoVue-Rare Sera Assay-Product Status 26

Table 47: ORTHO AutoVue-Rare Sera Assay-Product Description 26

Table 48: ORTHO BioVue-Rare Sera Assay-Product Status 27

Table 49: ORTHO BioVue-Rare Sera Assay-Product Description 27

Table 50: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview 28

Table 51: ALBAclone Anti-C beta Reagent-Product Status 28

Table 52: ALBAclone Anti-C beta Reagent-Product Description 29

Table 53: ALBAclone Anti-e beta Reagent-Product Status 29

Table 54: ALBAclone Anti-e beta Reagent-Product Description 29

Table 55: ALBAclone Anti-H Reagent-Product Status 29

Table 56: ALBAclone Anti-H Reagent-Product Description 30

Table 57: ALBAcyte O Adult i Cell Reagent-Product Status 30

Table 58: ALBAcyte O Adult i Cell Reagent-Product Description 30

Table 59: ALBAcyte O RhD VI Reagent Cells-Product Status 30

Table 60: ALBAcyte O RhD VI Reagent Cells-Product Description 31

Table 61: Eluate Kit-Product Status 31

Table 62: Eluate Kit-Product Description 31

Table 63: MosaiQ IH Microarray-Product Status 31

Table 64: MosaiQ IH Microarray-Product Description 32

Table 65: Polyagglutionation Kit-Product Status 32

Table 66: Polyagglutionation Kit-Product Description 32

Table 67: Sensitivity Kit Anti-S, K, e, C-Product Status 32

Table 68: Sensitivity Kit Anti-S, K, e, C-Product Description 33

Table 69: TBG Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

Table 70: HLAssure SE A Locus SBT Kit-Product Status 34

Table 71: HLAssure SE A Locus SBT Kit-Product Description 34

Table 72: HLAssure SE B Locus SBT Kit-Product Status 35

Table 73: HLAssure SE B Locus SBT Kit-Product Description 35

Table 74: HLAssure SE C Locus SBT Kit-Product Status 35

Table 75: HLAssure SE C Locus SBT Kit-Product Description 35

Table 76: HLAssure SE DQB Locus SBT Kit-Product Status 36

Table 77: HLAssure SE DQB Locus SBT Kit-Product Description 36

Table 78: HLAssure SE DRB-EX Locus SBT Kit-Product Status 36

Table 79: HLAssure SE DRB-EX Locus SBT Kit-Product Description 36

Table 80: Transfusion & Transplantation Technologies (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 37

Table 81: Aegis-Anti-A Quantitation In Group O Platelets-Product Status 37

Table 82: Aegis-Anti-A Quantitation In Group O Platelets-Product Description 37

Table 83: Aegis-Antibody Screening And Identification Assay-Product Status 38

Table 84: Aegis-Antibody Screening And Identification Assay-Product Description 38

Table 85: Aegis-Blood Grouping Assay-Product Status 38

Table 86: Aegis-Blood Grouping Assay-Product Description 39

Table 87: Aegis-Platelet Cross-match Assay-Product Status 39

Table 88: Aegis-Platelet Cross-match Assay-Product Description 39

Table 89: Aegis-Residual A Quantitation Assay-Product Status 40

Table 90: Aegis-Residual A Quantitation Assay-Product Description 40

Table 91: Aegis-rWBC Quantitation Assay-Product Status 40

Table 92: Aegis-rWBC Quantitation Assay-Product Description 40

Table 93: AEGIS System-Product Status 41

Table 94: AEGIS System-Product Description 41

Table 95: Glossary 97

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

AbSorber AB, ABO Diagnostic Test; Amity University, Blood Group Testing Kit; Arizona State University, Blood Screening Immunosignaturing; Biofortuna Ltd, HemoPlex Kell Genotyping Kit; Biofortuna Ltd, HemoPlex Kidd &; Duffy Genotyping Kit; Biofortuna Ltd, HemoPlex MNS Genotyping Kit; Biofortuna Ltd, HemoPlex Multi Blood Group Genotyping Kit; Biofortuna Ltd, HemoPlex RHCE Screening Kit; Biofortuna Ltd, HemoPlex RHCE Variant Genotyping Kit; Biofortuna Ltd, HemoPlex RHD &; CE Genotyping Kit; Biofortuna Ltd, HemoPlex RHD Variant Genotyping Kit; Biofortuna Ltd, ThromboPlex HPA Screening Kit; Grifols SA, IH Blood Genotyping (D) Kit; Haemonetics Corp, Blood Typing System; Immucor, Inc., NEO Iris; Ortho-Clinical Diagnostics Inc, ORTHO AutoVue - Rare Sera Assay; Ortho-Clinical Diagnostics Inc, ORTHO BioVue - Rare Sera Assay; Quotient Limited, ALBAclone Anti-C beta Reagent; Quotient Limited, ALBAclone Anti-e beta Reagent; Quotient Limited, ALBAclone Anti-H Reagent; Quotient Limited, ALBAcyte O Adult i Cell Reagent; Quotient Limited, ALBAcyte O RhD VI Reagent Cells; Quotient Limited, Eluate Kit; Quotient Limited, MosaiQ IH Microarray; Quotient Limited, Polyagglutionation Kit; Quotient Limited, Sensitivity Kit Anti-S, K, e, C; TBG Diagnostics Ltd, HLAssure SE A Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE B Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE C Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE DQB Locus SBT Kit; TBG Diagnostics Ltd, HLAssure SE DRB-EX Locus SBT Kit; Transfusion &; Transplantation Technologies (Inactive), Aegis - Anti-A Quantitation In Group O Platelets; Transfusion &; Transplantation Technologies (Inactive), Aegis - Antibody Screening And Identification Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Blood Grouping Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Platelet Cross-match Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - Residual A Quantitation Assay; Transfusion &; Transplantation Technologies (Inactive), Aegis - rWBC Quantitation Assay; Transfusion &; Transplantation Technologies (Inactive), AEGIS System


Companies

AbSorber AB

Amity University

Arizona State University

Biofortuna Ltd

Grifols SA

Haemonetics Corp

Immucor, Inc.

Ortho-Clinical Diagnostics Inc

Quotient Limited

TBG Diagnostics Ltd

Transfusion & Transplantation Technologies